Overview
- 5 inspections across 4 sites are on record.
- 20 Form 483 observations are attributed to this investigator.
- Most recent recorded activity is 2017-12-08.
At a glance
Inspections
5
Sites
4
Observations
20
Career since
Mar 2014
Recent inspections
Most recent inspections in the published record.
| Site | Date | Category | Form 483 |
|---|---|---|---|
| Oishi Koseido Co., Ltd. | 8 Dec 2017 | Human Drugs | |
| Oishi Koseido Co., Ltd. | 6 Dec 2017 | Human Drugs | |
| Fresenius Kabi USA, LLC | 30 Mar 2017 | Human Drugs | On file |
| Oishi Koseido Co., Ltd. | 29 Jan 2016 | Human Drugs | View 483 → |
| Boehringer Ingelheim Pharma GmbH & Co. KG | 7 Mar 2014 | Human Drugs | On file |
Sites inspected
Oishi Koseido Co., Ltd.Tosu, Japan2 insp.
Oishi Koseido Co., Ltd.Tosu, Japan1 insp.
Fresenius Kabi USA, LLCGrand Island, United States1 insp.
Boehringer Ingelheim Pharma GmbH & Co. KGIngelheim am Rhein, Germany1 insp.
Co-investigators
Investigators who share inspections with this person.
Vilmary Negron Rodriguez2 shared
Helen B Ricalde1 shared
Mindy M Chou1 shared
Jose A Cruz Gonzalez1 shared
Steven M Weinman1 shared
Andrew J Idzior1 shared
Margaret M Annes1 shared
Full investigator report
Get the verbatim findings behind Erika E Englund's 20 observations
Source 483 PDFs, verbatim observations, and how each site responded, so your team knows what they cite before they arrive.
- New inspections and Form 483s, mapped to the CFR citation
- Warning letter outcomes, and the citation patterns they repeat
- Their co-investigators, so no surprises about who shows up on site